$EXEL Headlines Apple, Tesla hit intraday reco

$EXEL Headlines

Apple, Tesla hit intraday records; Possible breach at Home Depot 3:15 p.m. Sept. 2, 2014 - Angela Johnson
Exelixis shares plunge 55% after disappointing trial results 9:40 a.m. Sept. 2, 2014 - Tomi Kilgore
Biotechs still sliding, but Wall Street says don't hit panic button just yet 2:43 p.m. March 26, 2014 - Russ Britt
HMA’s pre-emptive strike against ‘60 Minutes’ 5:44 p.m. Nov. 30, 2012 - Russ Britt
Chipotle vs. Taco Bell: testing Einhorn's thesis 6:37 a.m. Oct. 4, 2012 - The Trading Deck
Exelixis prices stock offering at 0.7% discount 12:21 p.m. Aug. 9, 2012 - MarketWatch.com
Exelixis slides 12% on stock, debt offering 3:39 p.m. Aug. 6, 2012 - Val Brickates Kennedy
FDA to speed Exelixis thyroid-cancer-drug review 6:35 a.m. July 30, 2012 - MarketWatch.com
Stocks to watch Thursday: GM, Agilent, NetApp 7:51 a.m. Feb. 16, 2012 - MarketWatch
Exelixis licenses cancer-drug R&D to Merck & Co. 8:26 a.m. Dec. 21, 2011 - MarketWatch.com
Loathe that investment theme? Perfect! 1:03 p.m. Nov. 8, 2011 - The Trading Deck
Exelixis plunges on drug study woes 12:05 p.m. Nov. 1, 2011 - Val Brickates Kennedy
Stocks to watch Tuesday: Exelixis, DirecTV, Leap 6:46 a.m. Nov. 1, 2011 - MarketWatch
Exelixis slides, Allstate up in after-hours trade 6:48 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis shares fall without FDA study commentary 6:05 p.m. Oct. 31, 2011 - Wallace Witkowski
Exelixis shares resume trading, drop 35% 5:44 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis rallies 21% on drug study 11:46 a.m. Oct. 24, 2011 - Val Brickates Kennedy
Icahn reports new stakes in Vector Group, El Paso 7:52 p.m. Aug. 15, 2011 - MarketWatch.com
ASCO studies shake up drug stocks 4:17 p.m. June 7, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 6:50 p.m. June 6, 2011 - Kate Gibson


Ad Comm smacks down Sonacare's HIFU device for prostate cancer 1:53 p.m. Oct. 3, 2014 - Seeking Alpha
Roche Presents Data on Cancer Immunotherapy Candidate - Analyst Blog 9:50 a.m. Oct. 3, 2014 - Zacks.com
Exelixis (EXEL) Is in Oversold Territory: What's Next? - Tale of the Tape 9:41 a.m. Oct. 3, 2014 - Zacks.com
Update: Exelixis Announces Very Positive Results From The CoBRIM Trial - Impacts To My Bull Thesis 9:57 a.m. Sept. 29, 2014 - Seeking Alpha
Exelixis up on clinical trial results 7:38 a.m. Sept. 29, 2014 - Seeking Alpha
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. 7:41 p.m. Sept. 28, 2014 - GuruFocus.com
Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape 8:53 a.m. Sept. 18, 2014 - Zacks.com
Anika Therapeutics: A Recent Greenblatt Small Cap Biotech Pick 8:38 a.m. Sept. 16, 2014 - Seeking Alpha
Tokai Pharmaceuticals IPO: Lack Of Product Diversity Should Leave Investors Cautious 8:41 a.m. Sept. 15, 2014 - Seeking Alpha
Exelixis' (EXEL) CEO Michael Morrissey Presents at Morgan Stanley Healthcare Conference (Transcript) 6:04 p.m. Sept. 9, 2014 - Seeking Alpha
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST 8:29 p.m. Sept. 6, 2014 - GuruFocus.com
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte 8:55 a.m. Sept. 5, 2014 - TheStreet.com
Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog 10:40 a.m. Sept. 3, 2014 - Zacks.com
Exelixis (EXEL) Enters Oversold Territory - Tale of the Tape 9:38 a.m. Sept. 3, 2014 - Zacks.com
Update: Exelixis COMET-1 Trial Fails: The Impact To My Bull Thesis 2:38 p.m. Sept. 2, 2014 - Seeking Alpha
Exelixis' CEO Presents at COMET-1 Results Conference (Transcript) 12:35 p.m. Sept. 2, 2014 - Seeking Alpha
Exelixis' (EXEL) CEO Mike Morrissey Hosts COMET-1 Results Conference (Transcript) 12:35 p.m. Sept. 2, 2014 - Seeking Alpha
After the Exelixis Implosion, Is There Anything Left Ahead? 10:10 a.m. Sept. 2, 2014 - 247WallSt.com
Benzinga's Top Downgrades 7:53 a.m. Sept. 2, 2014 - benzinga.com
Stifel Nicolaus Downgrades Exelixis To Hold 7:24 a.m. Sept. 2, 2014 - benzinga.com


Exelixis Announces Positive Results from Phase 3 Pivotal Trial ofCobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma 3:00 a.m. Sept. 29, 2014 - BusinessWire - BZX
Exelixis Announces Cobimetinib Phase3coBRIM Results toBePresented at ESMO 2014 Congress 1:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 8:40 a.m. Sept. 12, 2014 - PR Newswire - PRF
Exelixis to Present at theMorgan Stanley Global Healthcare Conference on Tuesday, September 9 4:05 p.m. Sept. 8, 2014 - BusinessWire - BZX
Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trialof Cabozantinib in Men with MetastaticCastration-ResistantProstate Cancer 6:00 p.m. Sept. 1, 2014 - BusinessWire - BZX
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 8:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Exelixis Announces Second Quarter 2014 Financial Results 4:14 p.m. July 31, 2014 - BusinessWire - BZX
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Biotech Companies Release Quarterly Financials and Announce Earnings Release Dates - Research Reports on Illumina, Alexion, Questcor, Jazz Pharmaceuticals and Exelixis 8:40 a.m. July 29, 2014 - PR Newswire - PRF
SEC Filings, Positive Trial Results, Technical Updates, and sNDA Updates - Analyst Notes on Questcor, Exelixis, InterMune, Progenics and Arrowhead 8:40 a.m. July 18, 2014 - PR Newswire - PRF
Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc. 3:05 p.m. July 17, 2014 - PR Newswire - PRF
Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014 4:06 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver 9:31 a.m. July 15, 2014 - PR Newswire - PRF
Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma 2:18 a.m. July 14, 2014 - BusinessWire - BZX
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis 7:00 a.m. July 10, 2014 - PR Newswire - PRF
Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10 4:15 p.m. June 3, 2014 - BusinessWire - BZX
Technical Coverage on Health Care Sector Equities -- Research on Arena Pharma, Exelixis, Dendreon, and Seattle Genetics 7:40 a.m. May 30, 2014 - PR Newswire - PRF
Exelixis Announces Presentation of Final Phase 1b Data for Cobimetinib in Combination with Vemurafenib atEADOCongress2014 1:01 a.m. May 7, 2014 - BusinessWire - BZX
Exelixis to Present at Two Investor Conferences in May 4:20 p.m. May 6, 2014 - BusinessWire - BZX
Technical Data on Biotech Stocks -- Research on Exact Sciences, Amgen, Exelixis, and Incyte 9:57 a.m. May 6, 2014 - PR Newswire - PRF